554 related articles for article (PubMed ID: 19658181)
1. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells.
Sherry MM; Reeves A; Wu JK; Cochran BH
Stem Cells; 2009 Oct; 27(10):2383-92. PubMed ID: 19658181
[TBL] [Abstract][Full Text] [Related]
2. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
3. The effects of type I interferon on glioblastoma cancer stem cells.
Du Z; Cai C; Sims M; Boop FA; Davidoff AM; Pfeffer LM
Biochem Biophys Res Commun; 2017 Sep; 491(2):343-348. PubMed ID: 28728846
[TBL] [Abstract][Full Text] [Related]
4. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
Leidgens V; Proske J; Rauer L; Moeckel S; Renner K; Bogdahn U; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
Oncotarget; 2017 Jan; 8(5):8250-8263. PubMed ID: 28030813
[TBL] [Abstract][Full Text] [Related]
5. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.
Zhang C; Mukherjee S; Tucker-Burden C; Ross JL; Chau MJ; Kong J; Brat DJ
Mol Oncol; 2017 Mar; 11(3):280-294. PubMed ID: 28100038
[TBL] [Abstract][Full Text] [Related]
6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
7. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
Villalva C; Martin-Lannerée S; Cortes U; Dkhissi F; Wager M; Le Corf A; Tourani JM; Dusanter-Fourt I; Turhan AG; Karayan-Tapon L
Int J Cancer; 2011 Feb; 128(4):826-38. PubMed ID: 20473906
[TBL] [Abstract][Full Text] [Related]
8. PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals.
Cenciarelli C; Marei HE; Felsani A; Casalbore P; Sica G; Puglisi MA; Cameron AJ; Olivi A; Mangiola A
Oncotarget; 2016 Aug; 7(33):53047-53063. PubMed ID: 27344175
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.
Wu J; Ji Z; Liu H; Liu Y; Han D; Shi C; Shi C; Wang C; Yang G; Chen X; Shen C; Li H; Bi Y; Zhang D; Zhao S
Toxicol Lett; 2013 Jun; 220(1):61-9. PubMed ID: 23542114
[TBL] [Abstract][Full Text] [Related]
10. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
[TBL] [Abstract][Full Text] [Related]
11. Activation of Aurora A kinase through the FGF1/FGFR signaling axis sustains the stem cell characteristics of glioblastoma cells.
Hsu YC; Kao CY; Chung YF; Lee DC; Liu JW; Chiu IM
Exp Cell Res; 2016 Jun; 344(2):153-66. PubMed ID: 27138904
[TBL] [Abstract][Full Text] [Related]
12. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
[TBL] [Abstract][Full Text] [Related]
14. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
[TBL] [Abstract][Full Text] [Related]
15. RBPJ contributes to the malignancy of glioblastoma and induction of proneural-mesenchymal transition via IL-6-STAT3 pathway.
Zhang G; Tanaka S; Jiapaer S; Sabit H; Tamai S; Kinoshita M; Nakada M
Cancer Sci; 2020 Nov; 111(11):4166-4176. PubMed ID: 32885530
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.
Garner JM; Fan M; Yang CH; Du Z; Sims M; Davidoff AM; Pfeffer LM
J Biol Chem; 2013 Sep; 288(36):26167-26176. PubMed ID: 23902772
[TBL] [Abstract][Full Text] [Related]
18. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
19. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
20. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
